Drug interactions between Gliadel and Tagamet HB
| Results for the following 2 drugs: |
|---|
| Gliadel (carmustine) |
| Tagamet HB (cimetidine) |
Interactions between your selected drugs
cimetidine ↔ carmustine
Applies to:Tagamet HB (cimetidine) and Gliadel (carmustine)
MONITOR CLOSELY: Coadministration with cimetidine may potentiate the myelosuppressive effects of systemic carmustine. The exact mechanism of interaction is unknown, but may involve additive myelosuppression or inhibition by cimetidine of the hepatic clearance of carmustine. In one study, marked neutropenia occurred in nine patients with glioblastomas who were administered carmustine, methylprednisolone, and cranial irradiation in combination with cimetidine (1200 mg/day for 1 to 4 weeks). The nadir in neutrophil cell counts in this group averaged 650 +/- 220/microL, compared to 2,160 +/- 240/microL in a group of 31 similarly treated patients who did not receive cimetidine. The neutropenia observed in the cimetidine-treated patients extended through day 42 of the treatment cycle, whereas patients who did not receive cimetidine did not experience significant neutropenia. In another study, leukopenia and thrombocytopenia occurred in 6 of 8 patients treated with carmustine, corticosteroids and cimetidine, compared to 6 out of 40 similarly treated patients who did not receive cimetidine. The interaction has not been studied with carmustine implants.
MANAGEMENT: Caution is advised if systemic carmustine is used in combination with cimetidine. Patients should be closely monitored for the development of delayed myelosuppression that may occur 4 to 6 weeks after carmustine administration. Blood counts are recommended weekly for at least 6 weeks after a dose. Alternatively, other H2-receptor antagonists such as ranitidine and famotidine may be considered in patients who require treatment with carmustine, since they have not been reported to cause the interaction and generally have minimal effects on hepatic metabolism.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
